Cryo-Cell has announced a research and development collaboration agreement with Cryopraxis Cryobiology.
Reportedly, the partnership would allow Cryopraxis to conduct clinical studies using Cryo-Cell’s proprietary C’elle menstrual stem technology (MenSCs), to identify potential future diagnostic and therapeutic uses in endometriosis and stress urinary incontinence in women.
The possible diagnostic test will be based on analyses of the menstrual blood stem cells, which will be collected using Cryo-Cell’s proprietary C’elle system, said the company.
Eduardo Cruz, founder and CEO of Cryopraxis Cryobiology, said: This research will determine if the stem cells found in menstrual blood can accurately provide a diagnosis that is highly precise, and this approach would offer women the added benefit of being both non-invasive and cost-effective. Additionally, this new method would potentially allow for earlier diagnosis of the disease, and subsequently enable women to seek relief from their symptoms sooner.
Mercedes Walton, chairman and CEO, Cryo-Cell, said: We are honored to partner with Cryopraxis, a global leader in regenerative medicine and stem cell R&D, to explore the utilization and potential commercialization of Cryo-Cell’s proprietary C’elle menstrual stem cell technology in the future development of novel therapies for two debilitating conditions affecting women worldwide.